ATE472336T1 - Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität - Google Patents
Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunitätInfo
- Publication number
- ATE472336T1 ATE472336T1 AT04796097T AT04796097T ATE472336T1 AT E472336 T1 ATE472336 T1 AT E472336T1 AT 04796097 T AT04796097 T AT 04796097T AT 04796097 T AT04796097 T AT 04796097T AT E472336 T1 ATE472336 T1 AT E472336T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- responses
- elicit
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000033289 adaptive immune response Effects 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 210000005007 innate immune system Anatomy 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51361403P | 2003-10-22 | 2003-10-22 | |
| US55984204P | 2004-04-06 | 2004-04-06 | |
| PCT/US2004/035041 WO2005042017A1 (en) | 2003-10-22 | 2004-10-22 | Compositions and methods for activating innate and allergic immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE472336T1 true ATE472336T1 (de) | 2010-07-15 |
Family
ID=34555907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04796097T ATE472336T1 (de) | 2003-10-22 | 2004-10-22 | Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8173140B2 (https=) |
| EP (2) | EP1689433B1 (https=) |
| JP (2) | JP4966661B2 (https=) |
| AT (1) | ATE472336T1 (https=) |
| CA (1) | CA2543080C (https=) |
| DE (1) | DE602004027940D1 (https=) |
| ES (2) | ES2615169T3 (https=) |
| WO (1) | WO2005042017A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524509B2 (en) * | 2001-03-09 | 2009-04-28 | Id Biomedical Corporation Of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| US7255867B2 (en) | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| WO2005042017A1 (en) * | 2003-10-22 | 2005-05-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| CN101039691B (zh) * | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| CN103800906B (zh) | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| WO2011106525A2 (en) | 2010-02-26 | 2011-09-01 | The Brigham And Women's Hospital, Inc. | Methods of treating cerebral amyloid angiopathy |
| US20140154288A1 (en) | 2011-05-13 | 2014-06-05 | Folia Biotech Inc. | Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| BR112021018086A2 (pt) * | 2019-03-14 | 2021-11-23 | Univ Arizona | Método de tratamento e/ou prevenção de asma, exacerbações de asma, asma alérgica e/ou condições associadas com microbiota relacionadas a distúrbios respiratórios |
| WO2021222354A2 (en) * | 2020-04-28 | 2021-11-04 | Nova Southeastern University | Compositions including alamandine peptides and methods for treatment of pulmonary disease using alamandine peptides |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| DE69625802T2 (de) * | 1995-03-13 | 2003-11-13 | The Secretary Of State For Defence, Salisbury | Impfstoffe gegen die pest |
| CN1211192A (zh) | 1995-09-18 | 1999-03-17 | 美国陆军医疗材料研究指挥部 | 生产非共价复合的多价蛋白体亚基疫苗的改进方法 |
| CA2400468C (en) | 2000-02-15 | 2012-12-18 | Intellivax International Inc. | Proteosome influenza vaccine |
| CN1549726A (zh) * | 2000-07-31 | 2004-11-24 | 耶鲁大学 | 先天性免疫系统指导的疫苗 |
| US7524509B2 (en) * | 2001-03-09 | 2009-04-28 | Id Biomedical Corporation Of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| EP1379552B2 (en) * | 2001-04-20 | 2014-11-19 | The Institute for Systems Biology | Toll-like receptor 5 ligands and methods of use |
| US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| WO2002100340A2 (en) * | 2001-06-08 | 2002-12-19 | Avant Immunotherapeutics, Inc. | Improved vaccination against anthrax |
| US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
| CA2524485A1 (en) * | 2003-05-05 | 2004-11-18 | Id Biomedical Corporation Of Quebec | Vaccinating against infectious diseases using proteosomes |
| US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| US20050152919A1 (en) * | 2003-09-15 | 2005-07-14 | Id Biomedical Corporation Of Quebec | Measles subunit vaccine |
| WO2005042017A1 (en) | 2003-10-22 | 2005-05-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| CN101039691B (zh) * | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| EP1778283A2 (en) | 2004-06-30 | 2007-05-02 | ID Biomedical Corporation of Quebec | Vaccine compositions for treating coronavirus infection |
| EP2274320A1 (en) * | 2008-04-25 | 2011-01-19 | ID Biomedical Corporation of Quebec | Methods for preparing immunogenic compositions |
-
2004
- 2004-10-22 WO PCT/US2004/035041 patent/WO2005042017A1/en not_active Ceased
- 2004-10-22 EP EP04796097A patent/EP1689433B1/en not_active Expired - Lifetime
- 2004-10-22 DE DE602004027940T patent/DE602004027940D1/de not_active Expired - Lifetime
- 2004-10-22 ES ES10001123.8T patent/ES2615169T3/es not_active Expired - Lifetime
- 2004-10-22 AT AT04796097T patent/ATE472336T1/de not_active IP Right Cessation
- 2004-10-22 CA CA2543080A patent/CA2543080C/en not_active Expired - Lifetime
- 2004-10-22 EP EP10001123.8A patent/EP2174665B1/en not_active Expired - Lifetime
- 2004-10-22 ES ES04796097T patent/ES2346441T3/es not_active Expired - Lifetime
- 2004-10-22 US US10/972,062 patent/US8173140B2/en not_active Expired - Lifetime
- 2004-10-22 JP JP2006536826A patent/JP4966661B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-28 US US12/111,093 patent/US20090324639A1/en not_active Abandoned
-
2011
- 2011-04-05 JP JP2011083368A patent/JP2011157380A/ja active Pending
-
2012
- 2012-04-26 US US13/457,223 patent/US8709447B2/en not_active Expired - Lifetime
-
2014
- 2014-04-28 US US14/263,390 patent/US9433672B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2174665B1 (en) | 2016-11-16 |
| US20140234374A1 (en) | 2014-08-21 |
| EP2174665A3 (en) | 2010-06-23 |
| JP4966661B2 (ja) | 2012-07-04 |
| ES2346441T3 (es) | 2010-10-15 |
| US9433672B2 (en) | 2016-09-06 |
| EP1689433A1 (en) | 2006-08-16 |
| DE602004027940D1 (de) | 2010-08-12 |
| EP2174665A2 (en) | 2010-04-14 |
| US20120276140A1 (en) | 2012-11-01 |
| CA2543080A1 (en) | 2005-05-12 |
| JP2011157380A (ja) | 2011-08-18 |
| US8173140B2 (en) | 2012-05-08 |
| EP1689433B1 (en) | 2010-06-30 |
| US20090324639A1 (en) | 2009-12-31 |
| ES2615169T3 (es) | 2017-06-05 |
| WO2005042017A1 (en) | 2005-05-12 |
| US20090318337A1 (en) | 2009-12-24 |
| US8709447B2 (en) | 2014-04-29 |
| JP2007509166A (ja) | 2007-04-12 |
| CA2543080C (en) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026584D1 (de) | Microbielles wirkstoffabgabesystem | |
| WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
| WO2000054803A3 (en) | Immunostimulatory nucleic acids and antigens | |
| WO2005089164A3 (en) | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions | |
| ATE472336T1 (de) | Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität | |
| WO2006135434A3 (en) | Semi-soft c-class immunostimulatory oligonucleotides | |
| CY1110727T1 (el) | Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση | |
| DE60207194D1 (de) | Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens | |
| WO2003092610A3 (en) | Methods of using cytokine antagonists to treat hiv infection and aids | |
| WO2007026190A3 (en) | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses | |
| TW200507874A (en) | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use | |
| WO2005111057A3 (en) | Immunostimulatory nucleic acids for inducing il-10 responses | |
| WO2004058157A3 (en) | Yeast-based vaccines as immunotherapy | |
| WO2001060402A3 (en) | Proteosome influenza vaccine | |
| WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
| WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
| ATE404196T1 (de) | Rapamycin und il-10 zur behandlung von autoimmunerkrankungen | |
| DE60144240D1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| WO2004032860A3 (en) | Hiv vaccine formulations | |
| EP4295862A3 (en) | Coronavirus vaccine | |
| CA2519806A1 (en) | Composition comprising iscom particles and live micro-organisms | |
| WO2002034287A3 (en) | Therapeutic vaccine formulations containing chitosan | |
| DE60109180D1 (de) | Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung | |
| ATE404152T1 (de) | Pathogene impstoffe und verfahren zur deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |